Skip to main content
PFE
NYSE Life Sciences

FDA Clears Durvalumab-Enfortumab Combo for Muscle Invasive Bladder Cancer

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$28.853
Mkt Cap
$164.455B
52W Low
$23.62
52W High
$31.44
52W Position info
22% above low
Off High info
8.2% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

PFE sits 22% above its 52-week low of $23.62.

Summary

The FDA approved durvalumab in combination with enfortumab vedotin-ejfv for muscle invasive bladder cancer, adding a label expansion in a setting where treatment options are limited. This is the second oncology approval for Pfizer in roughly five weeks, following the October 7 clearance of TUKYSA as maintenance therapy in HER2-positive metastatic breast cancer. The company is leaning on its oncology pipeline to offset a 40% drop in nine-month net income to $5.68 billion, driven by $4.3 billion of impairments, disclosed in the Q3 10-Q. The approval itself carries no disclosed revenue figure, so the near-term financial impact depends on how quickly the regimen is adopted in the perioperative setting.

At the time of this announcement, PFE was trading at $28.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $164.5B. The 52-week trading range was $23.62 to $31.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 11, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.45
Real-time Price: $28.93 info
Change: -$0.5225 (-2%) info
Market Cap: $164.669B info
PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $28.93 info
Change: -$1.73 (-6%) info
Market Cap: $164.669B info
PFE
Nov 03, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.62
Real-time Price: $28.93 info
Change: -$1.70 (-6%) info
Market Cap: $164.669B info
PFE
Nov 03, 2026, 6:55 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $30.73
Real-time Price: $28.93 info
Change: -$1.80 (-6%) info
Market Cap: $164.669B info
PFE
Nov 03, 2026, 6:45 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.98
Real-time Price: $28.93 info
Change: -$2.05 (-7%) info
Market Cap: $164.669B info